KCM
GLMD icon

Knoll Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Knoll Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-809
Closed -$696K – 20
2019
Q3 		$696K Sell
809
-336
-29% -$337K 0.64% 19
2019
Q2 		$1.51M Hold
1,145
– – 1.24% 13
2019
Q1 		$1.68M Sell
1,145
-22
-2% -$32K 1.28% 13
2018
Q4 		$1.43M Hold
1,167
– – 1.63% 8
2018
Q3 		$2.88M Hold
1,167
– – 2.44% 7
2018
Q2 		$2.5M Buy
+1,167
New +$1.69M 2.12% 8
2016
Q3 		– Sell
-277
Closed -$224K – 20
2016
Q2 		$224K Sell
277
-84
-23% -$79.4K 0.07% 20
2016
Q1 		$320K Hold
361
– – 0.13% 19
2015
Q4 		$495K Hold
361
– – 0.18% 17
2015
Q3 		$483K Hold
361
– – 0.21% 16
2015
Q2 		$654K Hold
361
– – 0.21% 15
2015
Q1 		$612K Hold
361
– – 0.18% 13
2014
Q4 		$377K Hold
361
– – 0.15% 12
2014
Q3 		$559K Hold
361
– – 0.22% 10
2014
Q2 		$633K Hold
361
– – 0.28% 10
2014
Q1 		$746K Buy
+361
New +$846K 0.39% 10

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Knoll Capital Management's GLMD Position: Q4 2019 in Review

Knoll Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2019, closing a stake of 809 shares — an estimated $696K sold.

Knoll Capital Management first reported a position in GLMD in Q1 2014 and held it in 16 quarters. The position peaked at $2.88M in Q3 2018. 31 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

  • Knoll Capital Management reported no remaining Galmed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Knoll Capital Management sold 809 Galmed Pharmaceuticals shares in Q4 2019, an estimated $696K.
  • Knoll Capital Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 16 quarters.
  • Knoll Capital Management's Galmed Pharmaceuticals position peaked at $2.88M in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on Knoll Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.